2009年,Legendre AM的实验小组对Sass and Sass生产的试验性药物“聚异戊烯免疫刺激剂”(英語:polyprenyl immunostimulant,简称PI)进行了实验,三只使用了PI的干性FIP患猫均生存了超过一年时间[34]。2017年,Legendre实验小组进行了60只干性FIP患猫范围的PI疗效实验,其中52只(87%)未能活过200天,但有4只(7%)生存了300天以上[35]。
另外,市面亦有辉瑞公司的PRIMUCELL鼻腔疫苗,但其预防效果具有争议。辉瑞公司在1991年取得该疫苗许可时进行的实验规模过小,且过于久远;其理论上起效条件也颇为苛刻,要求猫必须完全未曾接触猫冠状病毒,尽早断奶,此后彻底隔离,严格控制环境卫生,但这些措施仍无法完全保证猫不会患上FIP,因猫冠状病毒过于普遍。此外,该疫苗研发于20世纪70年代,彼时有关冠状病毒的研究和了解非常有限。美国猫科执业医师协会(英語:American Association of Feline Practitioners)以及欧洲猫科疾病顾问委员会(英語:European Advisory Board on Cat Diseases)均未建议使用该疫苗。
参考来源
^Pedersen, N. C.; Perron, M.; Bannasch, M.; Montgomery, E.; Murakami, E.; Liepnieks, M.; Liu, H. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2019-02-13, 21 (4): 271-281. PMID 30755068. doi:10.1177/1098612X19825701.
^Vogel, Liesbeth; Van der Lubben, Mariken; Te Lintelo, Eddie G.; Bekker, Cornelis P.J.; Geerts, Tamara; Schuijff, Leontine S.; Grinwis, Guy C.M.; Egberink, Herman F.; Rottier, Peter J.M. Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Veterinary Research. 2010-07-23, 41 (5): 71. doi:10.1051/vetres/2010043.
^Licitra, Beth N.; Millet, Jean K.; Regan, Andrew D.; Hamilton, Brian S.; Rinaldi, Vera D.; Duhamel, Gerald E.; Whittaker, Gary R. Mutation in Spike Protein Cleavage Site and Pathogenesis of Feline Coronavirus. Emerging Infectious Diseases. 2013-07, 19 (7): 1066–1073. doi:10.3201/eid1907.121094.
^Addie D; Belák S; Boucraut-Baralon C. Feline infectious peritonitis. ABCD guidelines on prevention and management. Journal of Feline Medicine & Surgery. 2009, 11 (7): 594-604.
^Porter E; Tasker S; Day MJ; Harly R; Kipar A; Siddell SG; Helps CR. Amino acid changes in the spike protein of feline coronavirus correlate with systemic spread of virus from the intestine and not with feline infectious peritonitis. Veterinary Research. 2014-04-05, 45 (1): 49-49.
^Pedersen NC; Eckstrand C; Liu H; Leutenegger C; Murphy B. Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. Veterinary Microbiology. 2015, 175 (2-4): 157-166.使用|accessdate=需要含有|url= (帮助)
^Pederson NC. An update on feline infectious peritonitis: virology and immunopathogenesis. Veterinary Journal. 2014, 201 (2): 123-132.
^Chang HW; Groot RJD; Egberink HF; Rottier PJM. Feline infectious peritonitis: insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the viral 3c gene. Journal of General Virology. 2010, 91 (2): 415.
^Bell ET; Toribio JA; White JD; Malik R; Norris JM. Seroprevalence study of feline coronavirus in owned and feral cats in Sydney, Australia. Australian Veterinary Journal. 2010, 84 (3): 74–81.使用|accessdate=需要含有|url= (帮助)
^Holst BS; Englund L; Palacios S; Renström L; Berndtsson LT. Prevalence of antibodies against feline coronavirus and Chlamydophila felis in Swedish cats.. Journal of Feline Medicine & Surgery. 2006, 8 (3): 207-211.
^Leutenegger CM; Hofmannlehmann R; Riols C; Liberek M; Worel G; Lups P; Fehr D; Hartmann M; Weilenmann P; Lutz H. VIRAL INFECTIONS IN FREE-LIVING POPULATIONS OF THE EUROPEAN WILDCAT. Journal of Wildlife Diseases. 1999, 35 (4): 678-86.
^ 17.017.117.2Jeffery, Unity; Deitz, Krysta; Hostetter, Shannon. Positive predictive value of albumin: globulin ratio for feline infectious peritonitis in a mid-western referral hospital population. Journal of Feline Medicine and Surgery. 2012-07-18, 14 (12): 903–905. doi:10.1177/1098612X12454862.
^Hoskins JD. Coronavirus infection in cats. Veterinary Clinics of North America Small Animal Practice. 1993, 23 (1): 1-16.
^ 19.019.1Evermann JF; Henry CJ; Marks SL. Feline infectious peritonitis. Journal of the American Veterinary Medical Association. 1995, 206 (8): 1130-4. doi:10.1036/1097-8542.757283.
^Olsen CW. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Veterinary Microbiology. 1993, 36 (1-2): 1-37.
^Felten, Sandra; Leutenegger, Christian M.; Balzer, Hans-Joerg; Pantchev, Nikola; Matiasek, Kaspar; Wess, Gerhard; Egberink, Herman; Hartmann, Katrin. Sensitivity and specificity of a real-time reverse transcriptase polymerase chain reaction detecting feline coronavirus mutations in effusion and serum/plasma of cats to diagnose feline infectious peritonitis. BMC Veterinary Research. 2017-08-02, 13 (1). doi:10.1186/s12917-017-1147-8.
^Doenges, SJ; Weber, K; Dorsch, R; Fux, R; Hartmann, K. Comparison of real-time reverse transcriptase polymerase chain reaction of peripheral blood mononuclear cells, serum and cell-free body cavity effusion for the diagnosis of feline infectious peritonitis.. Journal of feline medicine and surgery. 2017-04, 19 (4): 344–350. PMID 26787293. doi:10.1177/1098612X15625354.
^Longstaff, Louise; Porter, Emily; Crossley, Victoria J; Hayhow, Sophie E; Helps, Christopher R; Tasker, Séverine. Feline coronavirus quantitative reverse transcriptase polymerase chain reaction on effusion samples in cats with and without feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2016-07-10, 19 (2): 240–245. doi:10.1177/1098612X15606957.
^Riemer, Friederike; Kuehner, Kirsten A; Ritz, Susanne; Sauter-Louis, Carola; Hartmann, Katrin. Clinical and laboratory features of cats with feline infectious peritonitis – a retrospective study of 231 confirmed cases (2000–2010). Journal of Feline Medicine and Surgery. 2015-07-16, 18 (4): 348–356. doi:10.1177/1098612X15586209.
^Addie, Diane D. Feline infectious peritonitis and coronavirus : everything a cat lover needs to know. [Nice]: Melchizedek Publications. 2013. ISBN 978-1480208971.
^Hartmann, K; Ritz, S. Treatment of cats with feline infectious peritonitis.. Veterinary immunology and immunopathology. 2008-05-15, 123 (1-2): 172–5. PMID 18395801. doi:10.1016/j.vetimm.2008.01.026.
^Ishida, T; Shibanai, A; Tanaka, S; Uchida, K; Mochizuki, M. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis.. Journal of feline medicine and surgery. 2004-04, 6 (2): 107–9. PMID 15123155. doi:10.1016/j.jfms.2003.08.011.
^Ritz, S; Egberink, H; Hartmann, K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis.. Journal of veterinary internal medicine. 2006, 21 (6): 1193–7. PMID 18196725.
^Danilov, LL; Maltsev, SD; Deyeva, AV; Narovlyansky, AN; Sanin, AV; Ozherelkov, SV; Pronin, AV. Phosprenyl: a novel drug with antiviral and immunomodulatory activity.. Archivum immunologiae et therapiae experimentalis. 1996, 44 (5-6): 395–400. PMID 9017158.
^Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C.; Weerasekara, Sahani; Hua, Duy H.; Groutas, William C.; Chang, Kyeong-Ok; Pedersen, Niels C.; Perlman, Stanley. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLOS Pathogens. 2016-03-30, 12 (3): e1005531. doi:10.1371/journal.ppat.1005531.
^Pedersen, Niels C; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C; Eckstrand, Chrissy; Groutas, William C; Bannasch, Michael; Meadows, Juliana M; Chang, Kyeong-Ok. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2017-09-13, 20 (4): 378–392. doi:10.1177/1098612X17729626.
^Legendre, AM; Bartges, JW. Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis.. Journal of feline medicine and surgery. 2009-08, 11 (8): 624–6. PMID 19482534. doi:10.1016/j.jfms.2008.12.002.
^Legendre, AM; Kuritz, T; Galyon, G; Baylor, VM; Heidel, RE. Polyprenyl Immunostimulant Treatment of Cats with Presumptive Non-Effusive Feline Infectious Peritonitis In a Field Study.. Frontiers in veterinary science. 2017, 4: 7. PMID 28261584. doi:10.3389/fvets.2017.00007.
^Addie, D.; Jarrett, O. A study of naturally occurring feline coronavirus infections in kittens. Veterinary Record. 1992-02-15, 130 (7): 133–137. doi:10.1136/vr.130.7.133.